ESTRO 2024 - Abstract Book

S1527

Clinical - Lower GI

ESTRO 2024

low incidence of toxicity suggests maintaining a 50% starting DR for two weeks may not be necessary. Obtaining plasma uracil levels prior to commencing Capecitabine, then again in week one of treatment could facilitate closer monitoring of toxicity, and potentially allow for an earlier dose escalation.

Keywords: Genetic testing, Dose adjustments, Toxicity

References:

Amstuz, U. Henricks, L.M. Offer, S.M. Barbarino, J. Schellens, J.H. Swen, J.J. Caudle, R. and Schwab, M. (2017). Clinical Pharmacogenetics Implementation consortium (CPIC) Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing:2017 update. Available at: 29152729-supplement (cpicpgx.org) (Accessed 03/10/2023).

Clinical Commissioning Urgent Policy Statement Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies. NHS England. (2020). (Accessed 03/10/2023).

European Medicines Agency. (2020) EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. Available at: EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine | European Medicines Agency. Accessed 05/10/2023.

UK Chemotherapy Board (2020). Personalised Medicine Approach For Fluoropyrimidine-based Therapies.

With, M.D. Sadlon, A. Cecchin, E. Haufroid, V. Thomas, F. Joerger, M. and Largiader, C.R. (2023) Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO. 8(2).

1824

Digital Poster

Impact of dose intensification Radiochemotherapy for rectal cancer: a monoinstitutional experience

Marco Lucarelli 1,2 , Rosario Bonelli 1,2 , Monica Di Tommaso 1 , Marta Di Nicola 3 , Annamaria Porreca 3 , Domenico Genovesi 1,2 1 “SS Annunziata” Hospital, Radiation Oncology Unit, Chieti, Italy. 2 "G. d'Annunzio" University, Department of Medical, Oral and Biotechnologies Sciences, Chieti, Italy. 3 Biostatistics, Department of Medical, Oral and Biotechnologies Sciences, "G. d'Annunzio" University, Chieti, Italy

Purpose/Objective:

Aiming to improve clinical outcomes, a single-institution experience is reported in order to evaluate the impact of Mandard Tumor Regression Grade (TRG) on overall survival (OS), the disease-free survival (DFS) and the locoregional control (LC) of Locally Advanced Rectal Cancer (LARC) patients treated with dose intensification and concomitant Capecitabine in neoadjuvant Radio-Chemotherapy schedule.

Material/Methods: